| 1. | Studies on explosion pulsatile - release tablets of metoprolol fumarate in vitro 富马酸美托洛尔爆破型脉冲片体外实验研究 |
| 2. | The improvement of quality of life of patients with chronic heart failure by metoprolol 美托洛尔提高慢性心力衰竭患者生存质量的作用 |
| 3. | The evaluation on the therapeutic effect of intravenous metoprolol on patients with rapid atrial fibrillation 美托洛尔静脉注射治疗快速心房颤动疗效评价 |
| 4. | Comparative study of safety and efficacy of carvedilol and metoprolol in treating patients with essential hypertension 卡维地洛与美多心安对高血压患者治疗效果的比较研究 |
| 5. | Ventricular remodeling and cardiovascular events in patients with chronic heart failure and the interventional effects of metoprolol 慢性心力衰竭患者心室重构和心脏事件与美托洛尔的干预效应 |
| 6. | Observation the clinical effective of the 166 hypertension treatment by taking orally dosage enalapril maleate tablets , hydrochlorothiazide tabletsand metoprolol tartrate tablets 依那普利合用氢氯噻嗪倍他乐克治疗高血压166例疗效观察 |
| 7. | The cause of death was concluded to be severe hypotension , bradycardia and cardiac failure due to combined intoxication with verapamil , metoprolol and digoxin 死亡原因是维拉帕米、美多心安和地高辛联合中毒引起的严重低血压、心动过缓和心脏衰竭。 |
| 8. | Metoprolol / cyclodextrin inclusion compound was prepared by the co - precipitation method and its structure was examined by dsc and uv spectra . the formation of the inclusion compound was proved 摘要通过共沉淀法合成了美多心安-环糊精包合物,并使用差示扫描量热分析、紫外光谱等方法加以鉴定,证明了美多心安可以和-环糊精形成包合物。 |
| 9. | Methods fifty male wistar rats were established into ami model successfully and randomly divided into 5 groups equally , i . e . the model group , the high , middle and low dose pqs groups and the metoprolol group 方法选雄性wistar大鼠,成功制作ami大鼠模型50只,随机分为pqs大中小剂量组,倍他乐克组及模型组,同时建立假手术组及正常组,每组10只。 |
| 10. | The researchers beliee that , although refill compliance and persistence were similar for all three agents , twice - daily dosing of metoprolol in most patients , with possible acute withdrawal resulting from missed doses , may at least partly explain their findings 对研究对象的中位随访时间为15个月以上,在调整了包括代表目前使用药物和剂量的时间相依性变量、年龄、性别、充血性心力衰竭和其他并存疾病等变量后,醋丁洛尔和阿替洛尔组的死亡率明显低于美托洛尔组,危险比分别是0 . 71和0 . 79 。 |